BFC Planning’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
BFC Planning's DNLI Position: Q3 2026 in Review
BFC Planning held its Denali Therapeutics (DNLI) position steady in Q3 2026 at 30 shares worth $620. The position accounts for ﹤0.01% of the portfolio, ranked #3259.
BFC Planning first reported a position in DNLI in Q3 2024 and has held it in 9 quarters since. The position peaked at $2.21K in Q3 2024. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.
- BFC Planning held 30 shares of Denali Therapeutics worth $620 as of Q3 2026.
- BFC Planning left its Denali Therapeutics share count unchanged in Q3 2026.
- Denali Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3259 holding.
- BFC Planning first reported a position in Denali Therapeutics in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's Denali Therapeutics position peaked at $2.21K in Q3 2024.
- 217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.